%0 Journal Article
%T Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.
%A Tian J
%A Wang H
%A Lu C
%A Liu L
%A Zhang X
%A Xie Y
%A Li R
%A Lv X
%A Fu D
%A Zhang L
%A Fang X
%A Wang X
%A Hu J
%A Liu X
%A Huang X
%A Zhao Q
%A Luo N
%A Tang H
%A Zhong Z
%A He Y
%A Li L
%J Lung Cancer
%V 181
%N 0
%D 2023 07 20
%M 37244039
%F 6.081
%R 10.1016/j.lungcan.2023.107255
%X Microsatellite instability (MSI) is the first pan-cancer biomarker approved to guide immune checkpoint inhibitor therapy for MSI-high (MSI-H) solid tumors. In lung cancer, the MSI-H frequency is very low, and the genetic characteristics and prognosis of lung cancer with MSI-H were rarely reported.<BR>Next-generation sequencing and immunohistochemistry were used detect MSI status, tumor mutation burden (TMB) and PD-L1 expression.<BR>Among 12,484 lung cancer patients screened, 66 were found with MSI-H, the proportion was as low as 0.5%. Compared with Microsatellite stability (MSS), TMB was higher in MSI-H lung cancer patients, while PD-L1 expression showed no considerable difference between MSI-H and MSS. After propensity score matching, compared with MSS, the most common companion mutations in MSI-H were TP53, BRCA2, TGFBR2, PTEN and KMT2C. In MSI-H lung adenocarcinoma with EGFR mutation, TGFBR2 and ERBB2 had higher mutation frequency than in MSS.<BR>The current study reveals the genetic characteristics of MSI-H lung cancer, which advanced our understanding of MSI-H lung cancer.